Biodefense company PharmAthene Inc. said Monday that Brian A. Markison has been appointed to its board of directors, effective Sept. 22
Markison was recently named president and chief executive of Nycomed U.S., which is slated to be spun out following Takeda Pharmaceuticals' acquisition of Nycomed.
The executive also serves on the boards of companies Immunomedics Inc. and Rosetta Genomics Ltd.
PharmAthene shares added 2 cents to close at $2.22 before the appointment was announced.
